BeyondSpring posts investor deck highlighting plinabulin late-stage NSCLC program and immune-modulating approach
Reuters2026/08/16 01:53- BeyondSpring highlighted plinabulin as a late-stage immune modulator positioned for 2L/3L NSCLC, including post–PD-1/L1 progression.
- DUBLIN-3 Phase 3 (n=559) met its primary endpoint, showing OS HR 0.82; median OS 10.5 months vs 9.4 months.
- Trial data also showed PFS, ORR improvements; grade 4 neutropenia fell sharply, including 33.58% to 5.13% on day 8.
- Company outlined DUBLIN-4 confirmatory Phase 3 in non-squamous EGFR, ALK, ROS1, RET WT NSCLC post-immunotherapy; global N=442; primary endpoint OS.
- Study 303 in post-ICI metastatic NSCLC (n=47) reported confirmed ORR 18.2%; median PFS 7.0 months; 24-month OS 58%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nvidia quietly reduces OpenAI data center guarantee from 250 billions to below 120 billions
Nvidia and OpenAI are close to signing a data center financing agreement in Ohio. However, Nvidia's financial guarantee has been reduced from $250 billion to less than $120 billion, covering only about 5 GW of computing power for the project's first phase. This adjustment is a direct response to investor concerns about Nvidia's risk exposure—after the previous $250 billion guarantee plan was revealed, Nvidia's stock price fell 5% in a single day. The agreement could be signed as early as this weekend.

Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.